Source link : https://www.newshealth.biz/health-news/follicular-lymphoma-therapy-shows-cost-time-trade-offs/
TOPLINE: SAN DIEGO — Despite its significantly higher acquisition costs, lisocabtagene maraleucel (liso-cel, Breyanzi) demonstrated better survival and quality of life as well as fewer time toxicity challenges than mosunetuzumab in patients with follicular lymphoma who have received at least two prior lines of therapy, according to a modeling study presented at the American Society […]
Author : News Health
Publish date : 2024-12-20 05:52:13
Copyright for syndicated content belongs to the linked Source.